Diamyd, Inc. (formerly Nurel Therapeutics)

Diamyd, Inc. was formed through the acquisition of Nurel Therapeutics in December 2005 and is the wholly-owned US subsidiary of Diamyd Medical AB, a publicly traded company based in Stockholm, Sweden.  Diamyd Medical's lead product, Diamyd®, is a novel protein therapy for the prevention of the onset of diabetes and is currently in two Phase 2 clinical trials in Sweden.  At its Pittsburgh location, Diamyd is developing novel products for the treatment of diabetes and its complications including chronic pain and diabetic neuropathy.   Diamyd's proprietary nerve targeting delivery system was developed at the University of Pittsburgh and has numerous additional applications including potential therapies for the treatment of cancer and central nervous systems disorders.

www.diamyd.com

Fluorous Technologies, Inc.

Fluorous Technologies, Inc. (FTI) manufactures a variety of products that facilitate the use of fluorous chemistry in traditional and high-throughput synthesis. These products are marketed under the trade name FluoroFlash®, and include fluorous protecting groups, fluorous reagents for specific synthetic reactions, fluorous scavengers, fluorous building blocks, and fluorous sorbents in a variety of formats.

www.fluorous.com

Immunetrics, Inc.

Immunetrics is a bio-simulation company, founded in 2001, that specializes in in silico disease modeling.  Immunetrics modeling technology provides critical information to drug developers to accelerate and improve the drug discovery and development process, particularly in the identification of clinically relevant biomarkers.   Immunetrics has developed a predictive software model of the human response to inflammation and coagulation, which enables drug discovery and development firms to gain comprehensive insights into a compound before investing significant resources into time-intensive and costly animal testing and human clinical trials.

www.immunetrics.com

KeyBay Pharmaceutical

KeyBay Pharma is dedicated to the discovery, development and commercialization of the next generation of novel antibiotics.

Knopp Biosciences LLC

KNOPP BIOSCIENCES is a drug discovery and development company focused on delivering breakthrough treatments in neurological disorders through innovation, experience and partnership.  Knopp’s lead compound, KNS-760704 (dexpramipexole), is currently in late-stage clinical development for amyotrophic lateral sclerosis, with additional indications under investigation.

www.knoppbio.com